Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study Showing Evidence of Success in Treating Underlying Cause of Cystic Fibrosis
Nov. 2, 2011 | 2 min read

(Bethesda, Md.) -- The Cystic Fibrosis Foundation issued the following statement in response to study results published today by The New England Journal of Medicine offering first evidence that the underlying cause of cystic fibrosis in select patient groups can be treated through a new drug, Kalydeco™ (VX-770).

The New England Journal of Medicine study marks an important and exciting milestone for the cystic fibrosis community, and it confirms that we are one step closer to finding a cure for the disease,” said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. “Nearly every CF drug available today was made possible with Foundation support, and Vertex Pharmaceuticals' Kalydeco is the latest example of our venture philanthropy model at work. We are excited about the opportunity this treatment presents if approved by the FDA for those CF patients who can benefit from this new drug.”

Kalydeco, developed by Vertex Pharmaceuticals with CF Foundation support and research input, is the first CF drug to correct a specific genetic defect -- mutation G551D -- in select CF patient groups. The drug is currently under review for approval by the U.S. Food and Drug Administration. For more information, refer to Vertex's press release.

About the Cystic Fibrosis Foundation 

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The CF Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of CF Foundation support. Based in Bethesda, Md., the CF Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization.

Share this article
About the CF Foundation | CFTR Modulators | Drug Pipeline
Recent news
The CF Foundation’s 16th Annual Teen Advocacy Day Empowers Teens to Make Their Voice Heard
News | 4 min read
Cystic Fibrosis Community Perspectives Influence Future of CF Care Model
News | 4 min read
CF Foundation Adapts Registry Reporting to New Race-Neutral Standards
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.